Results 81 to 90 of about 3,808,290 (359)

Acute Lymphoblastic Leukemia [PDF]

Journal of the National Comprehensive Cancer Network, 2012
The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment ...
Joseph C, Alvarnas, Patrick A, Brown, Patricia, Aoun, Karen Kuhn, Ballen, Naresh, Bellam, William, Blum, Michael W, Boyer, Hetty E, Carraway, Peter F, Coccia, Steven E, Coutre, Jennifer, Cultrera, Lloyd E, Damon, Daniel J, DeAngelo, Dan, Douer, Haydar, Frangoul, Olga, Frankfurt, Salil, Goorha, Michael M, Millenson, Susan, O'Brien, Stephen H, Petersdorf, Arati V, Rao, Stephanie, Terezakis, Geoffrey, Uy, Meir, Wetzler, Andrew D, Zelenetz, Maoko, Naganuma, Kristina M, Gregory   +26 more
openaire   +2 more sources

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Disease and treatment burden in patients with leukaemia: family members/partner perspective

Frontiers in Hematology
BackgroundLeukaemia patients require comprehensive care, including treatment, hospital visits, and family support. An awareness of the impact of leukaemia on family members is crucial. The Acute Leukemia Advocates Network, Chronic Lymphoid Leukemia (CLL)
Esther Natalie Oliva, Tatyana Ionova, Samantha Nier, Zack Pemberton-Whiteley, Zack Pemberton-Whiteley, Nick York, Denis Costello, Sam Salek   +7 more
doaj   +1 more source

RNA INTERFERENCE (RNAI): AN EFFECTIVE WAY TO DEVELOP RATIONAL COMBINATION THERAPIES WITH HYPOMETHYLATING AGENTS IN ACUTE LEUKAEMIAS AND MYELODYSPLASTIC SYNDROME [PDF]

European Medical Journal Hematology, 2013
Therapeutic progress in aggressive myeloid malignancies such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and advanced myeloproliferative neoplasm (MPNs) has been slow.
Raoul Tibes
doaj  

Functional Genomic Landscape of Acute Myeloid Leukemia

Nature, 2018
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events.
J. Tyner, C. Tognon, D. Bottomly, Beth Wilmot, S. Kurtz, S. Savage, Nicola Long, Anna Reister Schultz, E. Traer, Melissa L. Abel, A. Agarwal, A. Blucher, U. Borate, Jade Bryant, Russell T. Burke, A. Carlos, Richie Carpenter, J. Carroll, B. Chang, Cody Coblentz, Amanda d’Almeida, R. Cook, A. Danilov, K. Dao, Michie Degnin, D. Devine, J. Dibb, David K Edwards, C. Eide, I. English, J. Glover, Rachel Henson, Hibery Ho, Abdusebur Jemal, Kara Johnson, Ryan C. Johnson, Brian Junio, A. Kaempf, Jessica T. Leonard, Chen-Jzong Lin, S. Liu, Pierrette Lo, M. Loriaux, Samuel B. Luty, T. Macey, Jason D. MacManiman, Jacqueline Martinez, M. Mori, D. Nelson, Ceilidh Nichols, Jill Peters, Justin W Ramsdill, Angela Rofelty, R. Schuff, R. Searles, E. Segerdell, Rebecca Smith, S. Spurgeon, Tyler Sweeney, Aashis Thapa, Corinne Visser, Jacob P. Wagner, Kevin Watanabe-Smith, Kristen Werth, Joelle Wolf, Libbey White, Amy Yates, Haijiao Zhang, C. Cogle, R. Collins, D. Connolly, M. Deininger, L. Drusbosky, C. Hourigan, C. Jordan, P. Kropf, Tara L. Lin, M. Martinez, B. Medeiros, Rachel R. Pallapati, D. Pollyea, R. Swords, J. Watts, S. Weir, D. Wiest, R. M. Winters, S. McWeeney, B. Druker   +87 more
semanticscholar   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia [PDF]

, 2000
At diagnosis, clonal gene rearrangement probes {[}retinoic acid receptor (RAR)-alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-beta, myeloid lymphoid leukemia (MLL) or cytokine genes (GM-CSF, G-CSF, IL-3 ...
Braun, S., Duell, T., Gerhartz, Helmut Heinrich, Mittermueller, J., Schmetzer, Helga Maria, Wiesner, D.   +5 more
core   +1 more source

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Blood, 2018
Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone methyltransferase disrupter of telomeric silencing 1-like (DOT1L).
E. Stein, G. Garcia-Manero, D. Rizzieri, R. Tibes, J. Berdeja, M. Savona, Mojca Jongen-Lavrenic, J. Altman, B. Thomson, S. Blakemore, S. Daigle, N. Waters, A. Suttle, A. Clawson, R. Pollock, A. Krivtsov, S. Armstrong, J. Dimartino, E. Hedrick, B. Löwenberg, M. Tallman   +20 more
semanticscholar   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria

Haematologica, 2010
Background Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma. The European Group for the Immunological Classification of Leukemias (EGIL) scoring system unambiguously defines MPAL expressing aberrant lineage markers ...
Ester Mejstrikova, Jana Volejnikova, Eva Fronkova, Katerina Zdrahalova, Tomas Kalina, Jaroslav Sterba, Yahia Jabali, Vladimir Mihal, Bohumir Blazek, Zdena Cerna, Daniela Prochazkova, Jiri Hak, Zuzana Zemanova, Marie Jarosova, Alexandra Oltova, Petr Sedlacek, Jiri Schwarz, Jan Zuna, Jan Trka, Jan Stary, Ondrej Hrusak   +20 more
doaj   +1 more source